Control treatments in biologics trials of rheumatoid arthritis were often not deemed acceptable in the context of care

Control treatments in RCTs of biologics in RA are often deemed not acceptable in the context of usual care, especially those for non-head-to-head RCTs. These findings raise ethical concerns and challenge the choice of the comparator in RCTs.